联合检测外周血及腹水中CK20水平对结直肠癌微转移的意义  

Combined Detection of CK20 in Peripheral Blood and Ascites and its Implications on Micrometastases of Patients with Colorectal Cancer

作　　者：孙立辉[1] 王大巍[1] 樊毅[1] 

机构地区：[1]辽宁医学院附属第三医院普外二科,辽宁锦州121000

出　　处：《辽宁医学院学报》2014年第4期30-32,共3页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的检测患者术前外周血和腹水中细胞角蛋白(CK20)的水平对结直肠癌微转移的意义。方法采用改进的T7-RNA聚合酶催化的荧光扩增法(FACTT-T7 RNA),通过与酶联免疫法(ELISA)和流式细胞学技术(FCM)的对比,对附属第三医院2012年11月至2013年11月收治的56例结直肠癌患者术前外周血和术中腹水的CK20水平进行检测评价。结果 56例结直肠癌患者术中,外周血CK20阳性率FACTT为57.14%(32/56),ELISA为25.00%(14/56);腹水CK20阳性率FACTT为30.36%(17/56),FCM为14.29%(8/56),组内对比差异具有统计学意义(P<0.05);FACTT方法检测外周血联合腹水CK20阳性检出率达73.21%(41/56),组间对比率差异具有显著统计学意义(分别为P<0.05,P<0.01),CK20的表达与肿瘤TNM分期、分化程度有关(P<0.05)。结论 FACTT方法联合检测外周血和腹水中CK20水平的阳性表达率高,对结直肠癌患者的微转移具有重要的临床意义。Objective To detect the level of CK20 in peripheral blood and ascites and its implications on micrometastases of patients with colorectal cancer. Methods The improved fluorescent amplification catalyzed byT7 polymerase technique（ FACTT-T7RNA） was adopted and through the comparison between the enzyme-linked immunosorbent assay（ELISA） and flow cytometry techniques（FCM）,CK20 levels of 56 patients with colorectal cancer from Nov. 2012 to Nov. 2013 was evaluated by preoperative blood and ascites. Results 56 patients with colorectal cancer,peripheral blood CK20 FACTT positive rate was 57. 14%（32 /56）,and ELISA was 25. 00%（14 /56）,ascites CK20 FACTT positive rate was 30. 36%（17 /56）,and FCM was 14. 29%（8 /56）,the differences between the two groups was of statistically significance（P〈 0. 05）,by FACTT technique,peripheral and ascites CK20 positive rate was 73. 21%（41 /56）,with significant difference（P〈 0. 05,P〈 0. 01） between the two groups. The level of CK20 expression related to TNM stage and Degree of differentiation（ P〈 0. 05）. Conclusion Positive expression of CK20 levels in peripheral blood and ascites was high through FACTT combined detection,which is of clinical significance to micrometastasis.

关 键 词：结直肠癌 细胞角蛋白CK20 微转移 T7-RNA聚合酶 

分 类 号：R735.3[医药卫生—肿瘤]